Abstracts tagged "hormones and rheumatoid arthritis (RA)"

Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Man Wai Tang¹, Frieda A. Koopman², Jan P.M. Visscher², Marjolein J.H. de Hair², Danielle M. Gerlag^2,3 and Paul P. Tak^2,4, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³GlaxoSmithKline, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…
Abstract Number: 358 • 2014 ACR/ARHP Annual Meeting
Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study
Mitra Pikwer¹, Cecilia Orellana², Henrik Källberg², Andreas Pikwer³, Carl Turesson⁴, Lars Klareskog⁵, Lars Alfredsson^6,7, Saedis Saevarsdottir⁸ and Camilla Bengtsson⁹, ¹Rheumatology Unit, Mälarhospital, Institute of Environmental Medicine, Eskilstuna, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Centre of Clinical Research Sörmland, Eskilstuna, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Malmö, Sweden, ⁵Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska institutet, Stockholm, Sweden, ⁶Institute of Environmental Medicine, Stockholm, Sweden, ⁷Centre of Occupational and Environmental Medicine, Stockholm, Sweden, ⁸Institute of Environmental Medicine, Karolinska Institutet,, Stockholm, Sweden, ⁹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Female sex and older age are known risk factors for rheumatoid arthritis (RA). The disease is however heterogeneous, and a common division occurs between…
Abstract Number: 411 • 2012 ACR/ARHP Annual Meeting
Early Menopause, Smoking and Circulating Antibodies Against Citrullinated Peptides in the Pre-Clinical Phase of Rheumatoid Arthritis
Mitra Pikwer¹, Johan Rönnelid², Monika Hansson³, Ulf Bergström¹, Lennart T.H. Jacobsson⁴, Linda Mathsson², Per Johan Jakobsson⁵, Guy B. Serre⁶, Rikard Holmdahl⁷, Lars Klareskog⁸ and Carl Turesson⁴, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Laboratory of Epidermis differentiation and Rheumatoid autoimmunity, Centre National de la Recherche Scientifique - Université de Toulouse, Toulouse, France, ⁷Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Previous studies indicate that anti-citrullinated peptide antibodies (ACPAs) may be detected in individuals who later develop rheumatoid arthritis (RA) years before onset, and that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].